Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 May;37(5):1115–1121. doi: 10.1128/aac.37.5.1115

In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.

L L Dever 1, J H Jorgensen 1, A G Barbour 1
PMCID: PMC187913  PMID: 8517700

Abstract

Borrelia burgdorferi, a spirochete and the causative agent of Lyme disease, has been reported to be susceptible to a variety of antimicrobial agents. In this investigation, the action of vancomycin, a glycopeptide antibiotic not previously known to have activity against spirochetes, against borrelias was examined. The in vitro activity of vancomycin against a variety of strains of B. burgdorferi and one strain of Borrelia hermsii was determined by use of a microdilution MIC method (L.L. Dever, J.H. Jorgensen, and A.G. Barbour, J. Clin. Microbiol. 30:2692-2697, 1992). MICs ranged from 0.5 to 2 micrograms/ml. MICs of the glycopeptides ristocetin and teicoplanin and the lipopeptide daptomycin against strain B31 of B. burgdorferi were all > or = 8 micrograms/ml. Subsurface plating, time-kill studies, synergy studies, and electron microscopy were used to investigate further the activity of vancomycin against B31. The MBC of vancomycin was 2 micrograms/ml. Time-kill curves demonstrated > or = 3-log10-unit (99.9%) killing of the final inoculum after 72 h by vancomycin concentrations twice the MIC. Synergy between vancomycin and penicillin was demonstrated at concentrations one-fourth the MIC of each drug. In electron microscopy, B31 cells exposed to vancomycin showed a disruption of cellular integrity and were indistinguishable from those exposed to penicillin. These studies demonstrate another class of microorganisms susceptible in vitro to vancomycin.

Full text

PDF
1115

Images in this article

1117Image
on p.1117
1118Image
on p.1118
1119Image
on p.1119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aber R. C., Wennersten C., Moellering R. C., Jr Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother. 1978 Sep;14(3):483–487. doi: 10.1128/aac.14.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agger W. A., Callister S. M., Jobe D. A. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother. 1992 Aug;36(8):1788–1790. doi: 10.1128/aac.36.8.1788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alborn W. E., Jr, Allen N. E., Preston D. A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Nov;35(11):2282–2287. doi: 10.1128/aac.35.11.2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arriaga P., Laynez J., Menendez M., Cañada J., Garcia-Blanco F. Thermodynamic analysis of the interaction of the antibiotic teicoplanin and its aglycone with cell-wall peptides. Biochem J. 1990 Jan 1;265(1):69–77. doi: 10.1042/bj2650069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barbour A. G., Hayes S. F. Biology of Borrelia species. Microbiol Rev. 1986 Dec;50(4):381–400. doi: 10.1128/mr.50.4.381-400.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barbour A. G., Todd W. J., Stoenner H. G. Action of penicillin on Borrelia hermsii. Antimicrob Agents Chemother. 1982 May;21(5):823–829. doi: 10.1128/aac.21.5.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bayer A. S., Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165. doi: 10.1093/infdis/151.1.157. [DOI] [PubMed] [Google Scholar]
  8. Bundoc V. G., Barbour A. G. Clonal polymorphisms of outer membrane protein OspB of Borrelia burgdorferi. Infect Immun. 1989 Sep;57(9):2733–2741. doi: 10.1128/iai.57.9.2733-2741.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chmara H., Ripa S., Mignini F., Borowski E. Bacteriolytic effect of teicoplanin. J Gen Microbiol. 1991 Apr;137(4):913–919. doi: 10.1099/00221287-137-4-913. [DOI] [PubMed] [Google Scholar]
  10. Dattwyler R. J., Halperin J. J., Pass H., Luft B. J. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis. 1987 Jun;155(6):1322–1325. doi: 10.1093/infdis/155.6.1322. [DOI] [PubMed] [Google Scholar]
  11. Dattwyler R. J., Halperin J. J., Volkman D. J., Luft B. J. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet. 1988 May 28;1(8596):1191–1194. doi: 10.1016/s0140-6736(88)92011-9. [DOI] [PubMed] [Google Scholar]
  12. Dever L. L., Jorgensen J. H., Barbour A. G. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol. 1992 Oct;30(10):2692–2697. doi: 10.1128/jcm.30.10.2692-2697.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ein M. E., Smith N. J., Aruffo J. F., Heerema M. S., Bradshaw M. W., Williams T. W., Jr Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 1979 Nov;16(5):655–659. doi: 10.1128/aac.16.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson R. C. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev Infect Dis. 1989 Sep-Oct;11 (Suppl 6):S1505–S1510. doi: 10.1093/clinids/11.supplement_6.s1505. [DOI] [PubMed] [Google Scholar]
  15. Johnson R. C., Kodner C. B., Jurkovich P. J., Collins J. J. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2133–2136. doi: 10.1128/aac.34.11.2133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jones R. N. Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1652–1653. doi: 10.1128/aac.33.9.1652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kenny M. T., Dulworth J. K., Brackman M. A. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci. Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):29–31. doi: 10.1016/0732-8893(91)90084-s. [DOI] [PubMed] [Google Scholar]
  18. Luft B. J., Volkman D. J., Halperin J. J., Dattwyler R. J. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann N Y Acad Sci. 1988;539:352–361. doi: 10.1111/j.1749-6632.1988.tb31869.x. [DOI] [PubMed] [Google Scholar]
  19. Massarotti E. M., Luger S. W., Rahn D. W., Messner R. P., Wong J. B., Johnson R. C., Steere A. C. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396–403. doi: 10.1016/0002-9343(92)90270-l. [DOI] [PubMed] [Google Scholar]
  20. Mirrett S., Reller L. B., Knapp J. S. Neisseria gonorrhoeae strains inhibited by vancomycin in selective media and correlation with auxotype. J Clin Microbiol. 1981 Jul;14(1):94–99. doi: 10.1128/jcm.14.1.94-99.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nadelman R. B., Luger S. W., Frank E., Wisniewski M., Collins J. J., Wormser G. P. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992 Aug 15;117(4):273–280. doi: 10.7326/0003-4819-117-4-273. [DOI] [PubMed] [Google Scholar]
  22. Nagarajan R. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother. 1991 Apr;35(4):605–609. doi: 10.1128/aac.35.4.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Paster B. J., Dewhirst F. E., Weisburg W. G., Tordoff L. A., Fraser G. J., Hespell R. B., Stanton T. B., Zablen L., Mandelco L., Woese C. R. Phylogenetic analysis of the spirochetes. J Bacteriol. 1991 Oct;173(19):6101–6109. doi: 10.1128/jb.173.19.6101-6109.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rahn D. W., Malawista S. E. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med. 1991 Mar 15;114(6):472–481. doi: 10.7326/0003-4819-114-6-472. [DOI] [PubMed] [Google Scholar]
  25. Rosa P. A., Schwan T. G. A specific and sensitive assay for the Lyme disease spirochete Borrelia burgdorferi using the polymerase chain reaction. J Infect Dis. 1989 Dec;160(6):1018–1029. doi: 10.1093/infdis/160.6.1018. [DOI] [PubMed] [Google Scholar]
  26. Shlaes D. M., Etter L., Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother. 1991 Apr;35(4):776–779. doi: 10.1128/aac.35.4.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Somma S., Gastaldo L., Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother. 1984 Dec;26(6):917–923. doi: 10.1128/aac.26.6.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Steere A. C., Green J., Schoen R. T., Taylor E., Hutchinson G. J., Rahn D. W., Malawista S. E. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med. 1985 Apr 4;312(14):869–874. doi: 10.1056/NEJM198504043121401. [DOI] [PubMed] [Google Scholar]
  29. Steere A. C. Lyme disease. N Engl J Med. 1989 Aug 31;321(9):586–596. doi: 10.1056/NEJM198908313210906. [DOI] [PubMed] [Google Scholar]
  30. Steere A. C., Pachner A. R., Malawista S. E. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med. 1983 Dec;99(6):767–772. doi: 10.7326/0003-4819-99-6-767. [DOI] [PubMed] [Google Scholar]
  31. Tsai T. F., Bailey R. E., Moore P. S. National surveillance of Lyme disease, 1987-1988. Conn Med. 1989 Jun;53(6):324–326. [PubMed] [Google Scholar]
  32. Williams D. H., Waltho J. P. Molecular basis of the activity of antibiotics of the vancomycin group. Biochem Pharmacol. 1988 Jan 1;37(1):133–141. doi: 10.1016/0006-2952(88)90765-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES